Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 7/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.41 |
| ▸ | PDE2A | O00408 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22381000 | 0.94 | ADA (0.72) | ADAPDE4BPDE2ACYP3A4PDE4A | |
| SCHEMBL22759880 | 0.78 | ADA (0.63) | ADAPDE4BPDE2ACYP3A4PDE4A | |
| SCHEMBL22326755 | 0.78 | ADORA2A (0.61) | ADAPDE4BPDE2ACYP3A4PDE4A | |
| SCHEMBL800129 | 0.77 | ADORA2A (0.57) | ADAPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL24236859 | 0.75 | ADA (0.54) | ADAPDE4BSMN1; SMN2 | |
| SCHEMBL23619216 | 0.75 | ADORA2A (0.61) | ADAPDE4BALDH1A1CYP1A2TSHR | |
| SCHEMBL21473256 | 0.74 | ADA (0.69) | ADAPDE4BPDE2ACYP3A4PDE4A | |
| SCHEMBL26160596 | 0.74 | ADA (0.48) | ADAPDE4BPDE2ACYP3A4PDE4A | |
| SCHEMBL23619425 | 0.73 | ADA (0.42) | ADAPDE4B | |
| SCHEMBL24971291 | 0.73 | ADA (0.71) | ADAPDE4BPDE2ACYP3A4PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230040920-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040920-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION | DNAJA1, DNAJA2, DNAJB11 | ADA 1608/4885PDE4B 902/4885PDE2A 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.